Desmorpholinyl Quizartinib-PEG2-COOH is primarily utilized in the development of targeted cancer therapies. It functions as a potent inhibitor of specific tyrosine kinases, which are often overactive in various cancers. The compound is engineered to enhance drug delivery and efficacy by incorporating a PEG2 linker, which improves solubility and stability in biological systems. This modification allows for better pharmacokinetics and reduced immunogenicity, making it suitable for conjugation with other therapeutic agents or nanoparticles. Its application is particularly significant in treating hematologic malignancies, such as acute myeloid leukemia (AML), where it targets FLT3 mutations. Additionally, the carboxyl group (-COOH) enables further functionalization, facilitating the creation of antibody-drug conjugates (ADCs) or other targeted delivery systems. This compound represents a promising approach in precision medicine, aiming to minimize off-target effects and improve patient outcomes.